Duloxetine · Cymbalta

Small molecule

Also known as LY248686

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder, Fibromyalgia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • CYMBALTA (duloxetine): chronic musculoskeletal pain
Product first approved 2004dailymed.nlm.nih.gov
EU
  • Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults.
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (92)
Diabetic Peripheral Neuropathic Pain
NCT01089556 · Eli Lilly and Company
2010-03 – 2011-11 · Diabetic Neuropathy, Painful
What this study did
NCT00641719 · Eli Lilly and Company
2008-03 – 2010-03 · Diabetic Neuropathies
What this study did
NCT00552175 · Eli Lilly and Company
2007-11 – 2009-03 · Diabetic Neuropathies
What this study did
Fibromyalgia
NCT01237587 · Eli Lilly and Company
2011-03 – 2017-11-28 · Fibromyalgia
What this study did
NCT01621191 · Eli Lilly and Company
2012-06 – 2014-02 · Fibromyalgia
What this study did
NCT01552057 · Eli Lilly and Company
2012-03 – 2013-12 · Fibromyalgia
What this study did
NCT00552682 · Germans Trias i Pujol Hospital
2007-01 – 2009-07 · Fibromyalgia, HIV-1 Infection
What this study did
NCT00125892 · Eli Lilly and Company
2005-07 – 2007-03 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT01226511 · Eli Lilly and Company
2011-06 – 2013-06 · Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
What this study did
NCT00803361 · Eli Lilly and Company
2008-12 – 2010-01 · Generalized Anxiety Disorder
What this study did
NCT00122850 · Eli Lilly and Company
2004-10 – 2005-11 · Anxiety Disorders
What this study did
Major Depressive Disorder
NCT03068247 · University of Utah
2021-11 – 2023-05 · Major Depressive Disorder
What this study did
NCT02417064 · Janssen Research & Development, LLC
2015-08-10 – 2018-02-20 · Treatment-resistant Depression
What this study did
NCT02493868 · Janssen Research & Development, LLC
2015-10-01 – 2018-02-16 · Depressive Disorder, Treatment-Resistant
What this study did
NCT02418585 · Janssen Research & Development, LLC
2015-08-07 – 2017-11-06 · Treatment-resistant Depression
What this study did
NCT02497287 · Janssen Research & Development, LLC
2015-09-30 – 2017-10-28 · Treatment-resistant Depression
What this study did
NCT02422186 · Janssen Research & Development, LLC
2015-08-20 – 2017-08-10 · Depressive Disorder, Treatment-Resistant
What this study did
NCT01360866 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2011-10 – 2017-05-18 · Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
What this study did
NCT00849901 · Eli Lilly and Company
2009-03 – 2011-10 · Major Depressive Disorder
What this study did
NCT00849693 · Eli Lilly and Company
2009-03 – 2011-09 · Major Depressive Disorder
What this study did
NCT00105989 · Eli Lilly and Company
2005-03 – 2008-01 · Depressive Disorder, Major
What this study did
NCT00384033 · Pfizer
2006-09 – 2007-09 · Depressive Disorder, Major
What this study did
NCT00321490 · AstraZeneca
2006-04 – 2007-05 · Major Depressive Disorder
What this study did
NCT00351910 · AstraZeneca
2006-05 – 2007-04 · Major Depressive Disorder
What this study did
NCT00366652 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-09 – 2006-09 · Depression, Depressive Disorder, Depressive Disorder, Major
What this study did
NCT00191594 · Eli Lilly and Company
2005-03 – 2006-08 · Major Depressive Disorder
What this study did
NCT00191919 · Eli Lilly and Company
2005-05 – 2006-05 · Depressive Disorder, Major
What this study did
NCT02232555 · Boehringer Ingelheim
2005-05 – 2006-05 · Depressive Disorder, Major
What this study did
NCT00191685 · Eli Lilly and Company
2004-05 – 2005-09 · Depressive Disorder, Major
What this study did
NCT00489775 · Eli Lilly and Company
2004-01 – 2005-06 · Major Depressive Disorder
What this study did
NCT00062673 · Eli Lilly and Company
2003-03 – 2004-07 · Depression, Cognition
What this study did
NCT00042562 · Eli Lilly and Company
2002-12 – 2003-12 · Major Depressive Disorder
What this study did
NCT00042575 · Eli Lilly and Company
2002-06 – 2002-08 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06407401 · European Organisation for Research and Treatment of Cancer - EORTC
2024-12 – 2028-11-30 · ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Drug-Related Side Effects and Adverse Reactions, Musculoskeletal Pain
What this study did
NCT06860984 · Tanta University
2025-03-10 – 2027-07-10 · Biliary Disease
What this study did
NCT06606067 · Parc de Salut Mar
2024-09-03 – 2026-12-31 · Chronic Post-surgical Pain
What this study did
Phase 2/3 (7)
Major Depressive Disorder
NCT00215228 · Duke University
2005-07 – 2007-08 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT04137107 · Alliance for Clinical Trials in Oncology
2020-06-17 – 2026-12-31 · Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
What this study did
NCT03037073 · Assiut University
2017-04-15 – 2019-11-30 · Postoperative Myalgia
What this study did
NCT00375973 · University of Cincinnati
2006-09 – 2014-03 · Fatigue Syndrome, Chronic
What this study did
NCT00457730 · Brown, Theodore R., M.D., MPH
2007-01 – 2012-08 · Multiple Sclerosis
What this study did
NCT00370656 · University of Surrey
2007-02 – 2009-05 · Diabetes Mellitus, Peripheral Neuropathies
What this study did
NCT00136383 · Duke University
2005-03 – 2007-06 · Depressive Symptoms
What this study did
Phase 2 (34)
Diabetic Peripheral Neuropathic Pain
NCT06614322 · University of Rochester
2026-02-02 – 2028-06-01 · Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
What this study did
NCT00837941 · Merck Sharp & Dohme LLC
2009-04 – 2009-09 · Painful Diabetic Neuropathy
What this study did
Major Depressive Disorder
NCT00529789 · Eli Lilly and Company
2007-08 – 2008-09 · Major Depressive Disorder
What this study did
NCT00331799 · Duke University
2007-04 – 2008-07 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07649291 · VA Office of Research and Development
2027-03-01 – 2032-09-01 · Knee Osteoarthritis, Pain, Depression
What this study did
NCT04970121 · Yan Yang, MD, Ph.D
2021-08-21 – 2027-12-01 · Chemotherapy-induced Peripheral Neuropathy, Pain, Solid Tumor
What this study did
NCT07431606 · University of Pennsylvania
2026-05-01 – 2027-10-31 · Inflammatory Bowel Diseases
What this study did
NCT06914557 · Fox Chase Cancer Center
2025-03-03 – 2027-06-30 · CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
What this study did
NCT04560673 · M.D. Anderson Cancer Center
2020-07-10 – 2026-12-31 · Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
What this study did
NCT05110144 · Mayo Clinic
2021-11-01 – 2026-12 · Refractory Chronic Cough
What this study did
NCT05120934 · Mayo Clinic
2021-11-01 – 2026-10 · Interstitial Lung Disease
What this study did
NCT06551051 · Fudan University
2024-08-06 – 2025-12-30 · Solid Tumour
What this study did
NCT04111627 · University of Maryland, Baltimore
2021-10-07 – 2025-08-11 · Knee Osteoarthritis, Depression
What this study did
NCT05611749 · Scripps Health
2023-05-30 – 2024-03-25 · Acute Post-operative Pain, Chronic Post Operative Pain, Narcotic Use, Opioid Use, Opioid Addiction
What this study did
NCT05486026 · Hawler Medical University
2022-08-20 – 2023-01-02 · Osteo Arthritis Knee
What this study did
NCT05115123 · Mansoura University
2022-03-02 – 2022-04-30 · Pain, Postoperative
What this study did
NCT04224584 · Kristian Kjær Petersen
2020-01-01 – 2021-07-01 · Osteoarthritis, Knee
What this study did
NCT04294953 · Assiut University
2020-03-01 – 2021-04-01 · Colorectal Cancer
What this study did
NCT04727502 · National Cancer Institute, Egypt
2020-12-20 – 2021-04 · Drug Effect
What this study did
NCT01846182 · VA Office of Research and Development
2015-06-24 – 2019-08-01 · Gulf War Illness
What this study did
NCT01912612 · University of Michigan Rogel Cancer Center
2013-10-30 – 2019-06-28 · Pain
What this study did
NCT03315533 · Rhode Island Hospital
2018-01-19 – 2019-04-01 · Musculoskeletal Pain
What this study did
NCT03038867 · Weill Medical College of Cornell University
2016-12-12 – 2018-08-31 · Infertility, Male, Depression
What this study did
NCT03364075 · Mark Ware
2017-09-01 – 2018-05-31 · Low Back Pain
What this study did
NCT02857244 · University of Chicago
2016-11 – 2017-11 · Parkinson's Disease
What this study did
NCT02307305 · Hanyang University Seoul Hospital
2014-08 – 2016-12 · Neuropathic Pain
What this study did
NCT00929344 · The Scripps Research Institute
2009-07 – 2014-10 · Alcohol Dependence
What this study did
NCT01223001 · Rehabilitation Hospital of Indiana
1996-09 – 2011-07 · Traumatic Brain Injury, Depression
What this study did
NCT00863057 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-05 – 2010-12 · HIV Infections, Peripheral Neuropathy
What this study did
NCT00940693 · Université de Montréal
2009-08 – 2010-12 · Attention Deficit Disorder With Hyperactivity
What this study did
NCT00190567 · Eli Lilly and Company
2001-10 – 2006-04 · Urinary Stress Incontinence
What this study did
NCT00190606 · Eli Lilly and Company
2002-01 – 2006-04 · Urinary Stress Incontinence
What this study did
NCT00475696 · Eli Lilly and Company
2002-11 – 2005-03 · Urinary Incontinence
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT05814640 · First Affiliated Hospital of Chongqing Medical University
2023-02-20 – 2027-07-01 · Depression, Sequestra
What this study did
NCT05949229 · Amira Hassan Ahmed Ali
2023-08 – 2026-12 · Post Operative Delirium
What this study did
NCT03110172 · Dalian Municipal Central Hospital
2017-01 – 2017-07 · Osteoarthritis Of Knee
What this study did
Phase 1 (22)
Diabetic Peripheral Neuropathic Pain
NCT05292066 · Aga Khan University
2022-10 – 2022-12 · Diabetic Peripheral Neuropathic Pain
What this study did
Major Depressive Disorder
NCT03623711 · Yuqi Cheng
2018-08-01 – 2022-12-31 · Major Depressive Disorder, Depression, Unipolar
What this study did
NCT02869035 · Copenhagen University Hospital, Rigshospitalet
2016-08 – 2019-07 · Major Depressive Disorder
What this study did
NCT00414323 · Eli Lilly and Company
2006-11 – 2007-05 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07400471 · Chattogram International Dental College
2026-02-06 – 2027-04-30 · Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain Sensitivity
What this study did
NCT04862845 · Cairo University
2021-07-30 – 2026-01-01 · Postoperative Pain
What this study did
NCT05065671 · Rutgers, The State University of New Jersey
2022-02-01 – 2025-09-23 · Microbial Colonization
What this study did
NCT03575403 · Craig Rush
2018-09-01 – 2023-03-15 · Alcohol Use Disorder
What this study did
NCT04178993 · Craig Rush
2019-09-01 – 2021-05-05 · Methamphetamine Use Disorder
What this study did
NCT04723238 · Laboratorios Andromaco S.A.
2021-01-23 – 2021-03-26 · Bioequivalence
What this study did
NCT04751318 · Laboratorios Andromaco S.A.
2021-02-27 – 2021-03-16 · Bioequivalence
What this study did
NCT02700711 · University of Kentucky
2016-02 – 2018-06 · Cocaine Use Disorder
What this study did
NCT01688570 · Medical College of Wisconsin
2011-08 – 2015-05 · Stroke
What this study did
NCT02174822 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2014-01 – 2014-04 · Drug-drug Interaction
What this study did
NCT00990067 · University Hospital, Basel, Switzerland
2009-11 – 2010-05 · Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders
What this study did
NCT00933452 · Shanghai Mental Health Center
2009-07 – 2009-12 · Healthy
What this study did
NCT00763178 · Yale University
2007-02 – 2009-12 · Posttraumatic Stress Disorder
What this study did
NCT02291367 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-05 · Healthy
What this study did
NCT02291341 · Dr. Reddy's Laboratories Limited
2008-05 – 2008-05 · Healthy
What this study did
NCT00533026 · Eli Lilly and Company
2007-07 – 2007-10 · Anticoagulant Effect of Warfarin When Taken With Duloxetine.
What this study did
NCT00387413 · GlaxoSmithKline
2006-10-02 – 2007-05-31 · Hyperalgesia
What this study did
NCT02232542 · Boehringer Ingelheim
2003-06 – 2003-08 · Healthy
What this study did
Phase 4 (107)
Diabetic Peripheral Neuropathic Pain
NCT05296759 · Alexandria University
2021-02-01 – 2022-03-08 · Diabetic Neuropathies
What this study did
NCT04246619 · KRKA
2019-11-12 – 2021-12-21 · Painful Diabetic Peripheral Neuropathy
What this study did
NCT02417935 · Eli Lilly and Company
2015-04 – 2017-05-13 · Diabetic Peripheral Neuropathic Pain
What this study did
NCT00619983 · Wake Forest University
2008-02 – 2013-05 · Diabetic Neuropathic Pain, Chronic Low Back Pain
What this study did
NCT01116531 · Turku University Hospital
2010-04 – 2012-12 · Diabetic Polyneuropathy, Postherpetic Neuralgia
What this study did
NCT00844194 · Boehringer Ingelheim
2009-02 – 2010-06 · Diabetic Neuropathies, Depressive Disorder, Major
What this study did
NCT00385671 · Eli Lilly and Company
2006-09 – 2009-11 · Diabetic Neuropathy, Painful
What this study did
NCT00322621 · Eli Lilly and Company
2006-04 – 2007-10 · Diabetic Neuropathies
What this study did
NCT00266643 · Eli Lilly and Company
2005-12 – 2007-04 · Diabetic Neuropathy, Painful
What this study did
Fibromyalgia
NCT01619566 · University of California, San Diego
2012-06 – 2015-01 · Fibromyalgia
What this study did
NCT01077375 · Forest Laboratories
2010-02 – 2011-01 · Fibromyalgia
What this study did
NCT00965081 · Eli Lilly and Company
2009-09 – 2010-11 · Fibromyalgia, Primary, Fibromyalgia, Secondary
What this study did
NCT01089621 · Eli Lilly and Company
2010-03 – 2010-08 · Fibromyalgia
What this study did
NCT00673452 · Eli Lilly and Company
2008-06 – 2009-07 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT01118780 · Eli Lilly and Company
2010-10 – 2012-07 · Generalized Anxiety Disorder
What this study did
NCT00961298 · West Penn Allegheny Health System
2009-09 – 2011-12 · Irritable Bowel Syndrome, Generalized Anxiety Disorder
What this study did
Major Depressive Disorder
NCT04388189 · Alto Neuroscience
2020-10-15 – 2023-05-30 · Major Depressive Disorder
What this study did
NCT04697693 · New York State Psychiatric Institute
2021-03-03 – 2021-05-20 · Post Traumatic Stress Disorder, Major Depressive Disorder
What this study did
NCT02711215 · Medical University of Vienna
2015-05 – 2020-01 · Major Depressive Disorder
What this study did
NCT01764867 · Shanghai Mental Health Center
2012-06 – 2014-12 · Major Depressive Disorder
What this study did
NCT01754493 · New York State Psychiatric Institute
2008-12 – 2014-12 · Major Depression, Irritable Bowel Syndrome
What this study did
NCT01391221 · Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
2011-07 – 2013-08 · Major Depression
What this study did
NCT01051466 · Eli Lilly and Company
2010-01 – 2013-03 · Major Depressive Disorder, Healthy Participants
What this study did
NCT00889369 · Hamilton Health Sciences Corporation
2009-05 – 2012-06 · Major Depressive Disorder
What this study did
NCT00960986 · Eli Lilly and Company
2009-08 – 2011-04 · Major Depressive Disorder (MDD)
What this study did
NCT01070329 · Eli Lilly and Company
2010-03 – 2011-03 · Major Depressive Disorder
What this study did
NCT00985504 · Eli Lilly and Company
2009-09 – 2010-12 · Major Depressive Disorder
What this study did
NCT01000805 · Eli Lilly and Company
2009-11 – 2010-10 · Major Depressive Disorder
What this study did
NCT00696293 · University of Pittsburgh
2007-05 – 2010-04 · Major Depressive Disorder, Back Pain, Aged
What this study did
NCT00810069 · Eli Lilly and Company
2008-11 – 2010-03 · Major Depressive Disorder
What this study did
NCT00406848 · Eli Lilly and Company
2006-11 – 2009-11 · Major Depressive Disorder
What this study did
NCT00696774 · Eli Lilly and Company
2008-06 – 2009-07 · Depressive Disorder, Major
What this study did
NCT00437125 · Eli Lilly and Company
2007-03 – 2009-07 · Major Depressive Disorder, Idiopathic Parkinson Disease
What this study did
NCT01035073 · University of Pennsylvania
2006-04 – 2009-05 · Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
What this study did
NCT00532480 · Indiana University
2007-09 – 2009-04 · Major Depression
What this study did
NCT00536471 · Eli Lilly and Company
2007-09 – 2008-12 · Major Depressive Disorder
What this study did
NCT02229825 · Boehringer Ingelheim
2007-02-09 – 2008-08-26 · Depressive Disorder, Major
What this study did
NCT00422162 · Eli Lilly and Company
2007-02 – 2008-08 · Major Depressive Disorder
What this study did
NCT00517985 · University of Arizona
2007-02 – 2008-06 · Major Depressive Disorder
What this study did
NCT00531895 · Kraepelin Psiquiatria Clinica
2006-04 – 2007-03 · Major Depression, Chronic Primary Headache
What this study did
NCT00191932 · Eli Lilly and Company
2004-08 – 2006-03 · Major Depressive Disorder
What this study did
NCT00191061 · Eli Lilly and Company
2004-10 – 2006-01 · Depressive Disorder
What this study did
NCT00479726 · Eli Lilly and Company
2004-08 – 2005-01 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT06232473 · Aarhus University Hospital
2024-01-01 – 2029-11-01 · Functional Disorder
What this study did
NCT07759336 · Benedict Alter
2026-09-15 – 2029-03 · Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
What this study did
NCT05851898 · Wake Forest University Health Sciences
2024-04-08 – 2028-12 · Depression in Old Age, Fragility Fracture
What this study did
NCT06245109 · Northwestern University
2024-02-26 – 2028-03-15 · Knee Osteoarthritis
What this study did
NCT06423716 · Sunnybrook Health Sciences Centre
2024-11-01 – 2027-12-31 · Knee Osteoarthritis
What this study did
NCT05851976 · Montefiore Medical Center
2023-10-04 – 2027-05 · Back Pain, Low
What this study did
NCT05976347 · Wake Forest University Health Sciences
2025-06-25 – 2027-05 · Depression
What this study did
Early phase / not applicable (54)
Diabetic Peripheral Neuropathic Pain
NCT07785544 · Bangladesh Medical University
2026-09-20 – 2027-08 · Painful Diabetic Peripheral Neuropathy
What this study did
Fibromyalgia
NCT07326163 · Bilecik Seyh Edebali Universitesi
2026-03-01 – 2027-01-01 · Fibromyalgia, Aromatherapy, Cost
What this study did
NCT04316702 · Assaf-Harofeh Medical Center
2020-03-01 – 2023-11-30 · Fibromyalgia, Emotional Trauma
What this study did
NCT03325959 · Assaf-Harofeh Medical Center
2017-03-01 – 2022-06-01 · Fibromyalgia, Hyperbaric Oxygen
What this study did
NCT05937711 · Ilker Fatih Sari
2020-11-02 – 2022-05-23 · Fibromyalgia
What this study did
NCT01127490 · Albany Medical College
2010-05-05 – 2015-09-09 · Fibromyalgia
What this study did
NCT01268631 · Tel-Aviv Sourasky Medical Center
2011-01 – 2013-01 · Fibromyalgia
What this study did
Generalized Anxiety Disorder
NCT00491348 · National Taiwan University Hospital
2007-04 – 2008-11 · Worry, Anxiety
What this study did
Major Depressive Disorder
NCT04847245 · Peking University
2021-05-01 – 2023-03-01 · Chronic Visceral Pain, Major Depressive Disorder
What this study did
NCT03121573 · Taichung Veterans General Hospital
2014-12-15 – 2017-01-17 · Major Depressive Disorder
What this study did
NCT01896349 · Hospital de Clinicas de Porto Alegre
2013-04 – 2014-11 · Treatment Resistant Depression
What this study did
NCT01650740 · Sunnybrook Health Sciences Centre
2012-08 – 2014-11 · Major Depressive Disorder
What this study did
NCT00617045 · Yale University
2007-07 – 2013-05 · Postpartum Depression, Major Depressive Disorder
What this study did
NCT00933439 · University of Texas Southwestern Medical Center
2005-02 – 2007-09 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT07731750 · University of Michigan
2026-07-23 – 2030-07 · Chronic Low-back Pain
What this study did
NCT07421427 · Cairo University
2026-02-21 – 2027-01-01 · Amantadine, Duloxetine, Pregabalin, Mastectomy, Pain Syndrome
What this study did
NCT05311774 · Assiut University
2022-04-01 – 2025-10-01 · Cancer Pain
What this study did
NCT06087211 · National Cancer Institute, Egypt
2023-10-10 – 2025-01-01 · Duloxetine, Magnesium Sulphate, Post-mastectomy Pain Syndrome
What this study did
NCT06429605 · Erzincan Military Hospital
2024-05-20 – 2024-12-27 · Vaginal Hysterectomy, Postoperative Pain, vNOTES
What this study did
NCT05256342 · Rambam Health Care Campus
2021-12-30 – 2024-04-08 · Knee, Osteoarthritis (OA), Biomarkers for Prediction of OA Treatment Efficacy
What this study did
NCT04313335 · Beijing Tiantan Hospital
2021-03-01 – 2023-05-16 · Postherpetic Neuralgia
What this study did
NCT05442268 · Tanta University
2022-07-16 – 2023-01-31 · Modified Radical Mastectomy, Postoperative Analgesia
What this study did
NCT04719585 · The Catholic University of Korea
2021-01 – 2022-12 · Total Knee Arthroplasty, Osteoarthritis, Knee
What this study did
NCT04732455 · Gamal Mohamed Taha Abouelmagd
2021-01-15 – 2022-07-05 · Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer
What this study did
NCT03148522 · Peking University
2017-06-01 – 2022-06-30 · Diagnosis and Treatment of Depression
What this study did
NCT03276689 · Rambam Health Care Campus
2017-10-19 – 2020-12-30 · Neuropathic Pain
What this study did
NCT03880916 · The Catholic University of Korea
2019-03-30 – 2020-03-31 · Osteoarthritis, Knee
What this study did
NCT03560427 · Assiut University
2018-09-10 – 2020-03-14 · Acute Pain
What this study did
NCT04140253 · Comenius University
2019-02-01 – 2020-03-10 · Stress Urinary Incontinence in Women
What this study did
NCT03468348 · Assiut University
2018-04-01 – 2020-02-10 · Acute Pain
What this study did
NCT03549026 · Assiut University
2018-01-05 – 2019-12-25 · Acute Pain
What this study did
NCT02655354 · University of Washington
2015-10 – 2019-11 · Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
What this study did
NCT03054220 · Jules Desmeules
2016-07 – 2018-12 · Healthy
What this study did
NCT03350334 · Acibadem University
2017-12-04 – 2018-03-15 · Laparoscopic Hysterectomy, Postoperative Recovery, Postoperative Pain
What this study did
NCT01470352 · d_yarnitsky
2011-11-16 – 2017-11-06 · Migraine
What this study did
NCT02672202 · Rambam Health Care Campus
2016-02 – 2017-05 · Post-operative Chronic Pain
What this study did
NCT02600247 · The Catholic University of Korea
2015-11 – 2016-11 · Osteoarthritis
What this study did
NCT00360399 · Emory University
2006-08 – 2015-04 · Depression
What this study did
NCT02020122 · Rambam Health Care Campus
2014-01 – 2015-01 · Pain
What this study did
NCT01470339 · Rambam Health Care Campus
2011-12 – 2014-07 · Pain
What this study did
NCT01359514 · Rambam Health Care Campus
2008-04 – 2014-01 · Pain
What this study did
NCT01363284 · Rambam Health Care Campus
2010-06 – 2012-08 · Diabetes, Painful Neuropathy
What this study did
NCT01269866 · Dr. Jesus Gutierrez Stone
2010-12 – 2012-05 · Systemic Lupus Erythematosus
What this study did
NCT00660751 · Rambam Health Care Campus
2007-08 – 2012-04 · Healthy
What this study did
NCT01404871 · Sunnybrook Health Sciences Centre
2009-04 – 2011-12 · Obsessive Compulsive Disorder
What this study did
NCT02903238 · Northwestern University
2011-07 – 2011-12 · Pain, Osteoarthritis
What this study did
NCT00981149 · University of Maryland, Baltimore
2009-05 – 2011-12 · Temporomandibular Joint Disorders
What this study did
NCT01028352 · University of Michigan Rogel Cancer Center
2008-10 – 2011-10 · Breast Cancer
What this study did
NCT01425827 · University of Alexandria
2010-11 – 2011-07 · Pain Reduction, Function Improvement
What this study did
NCT00388414 · Stanford University
2006-09 – 2010-01 · Low Back Pain
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Diabetic Peripheral Neuropathic Pain
NCT06715462 · Eurofarma Laboratorios S.A.
2026-04 – 2028-03 · Painful Diabetic Peripheral Neuropathy (PDPN)
What this study did
Generalized Anxiety Disorder
NCT00730691 · Takeda
2008-06 – 2009-02 · Generalized Anxiety Disorder
What this study did
Major Depressive Disorder
NCT07253207 · Zhejiang Huahai Pharmaceutical Co., Ltd.
2024-10-17 – 2025-07-22 · Major Depressive Disorder (MDD)
What this study did
NCT04364997 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2020-06-18 – 2021-09-22 · Major Depressive Disorder
What this study did
NCT01153009 · Takeda
2010-06 – 2012-03 · Depressive Disorder, Major
What this study did
NCT00672620 · Takeda
2008-04 – 2008-12 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT05840562 · Institut Cancerologie de l'Ouest
2023-10-20 – 2028-03 · Chemotherapy-induced Peripheral Neuropathy
What this study did
NCT06025474 · Federico II University
2023-01-01 – 2024-07-24 · Burning Mouth Syndrome
What this study did
Phase 2/3 (2)
Fibromyalgia
NCT03487211 · Shaheed Zulfiqar Ali Bhutto Medical University
2018-04-09 – 2020-02-26 · Fibromyalgia
What this study did
Other / comorbidity
NCT05786599 · University of British Columbia
2025-03-21 – 2026-03 · Chemotherapy-induced Peripheral Neuropathy
What this study did
Phase 2 (13)
Diabetic Peripheral Neuropathic Pain
NCT07882238 · Assiut University
2026-11 – 2027-12 · Diabetic Peripheral Neuropathy, Painful Diabetic Neuropathy, Diabetic Foot Pain, Neuralgia
What this study did
NCT01579279 · AbbVie (prior sponsor, Abbott)
2012-04 – 2012-05 · Diabetic Neuropathic Pain
What this study did
NCT00507936 · AbbVie (prior sponsor, Abbott)
2007-08 – 2008-10 · Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
What this study did
NCT00603265 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2007-11 – 2008-08 · Peripheral Neuropathy, Neuropathic Pain
What this study did
Major Depressive Disorder
NCT06842992 · Jiangsu Nhwa Pharmaceutical Co., Ltd.
2024-12-04 – 2025-09-12 · Major Depressive Disorder (MDD)
What this study did
NCT05018013 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-08-21 – 2022-12-30 · Major Depressive Disorder (MDD)
What this study did
NCT01564862 · Takeda
2012-04 – 2014-02 · Depressive Disorder, Major
What this study did
NCT01369095 · Bristol-Myers Squibb
2011-07 – 2013-05 · Depression
What this study did
NCT01309945 · Bristol-Myers Squibb
2011-04 – 2013-01 · Depression
What this study did
NCT01288079 · AstraZeneca
2011-02 – 2012-08 · Major Depressive Disorder
What this study did
NCT01145755 · AstraZeneca
2010-05 – 2010-11 · Major Depressive Disorder
What this study did
NCT00599911 · H. Lundbeck A/S
2007-10 – 2009-04 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT03812523 · Southeastern Regional Medical Center
2019-06 – 2021-10 · Chemotherapy-Induced Peripheral Neuropathy
What this study did
Phase 1 (1)
Fibromyalgia
NCT05508516 · China-Japan Friendship Hospital
2022-09-01 – 2024-10-18 · Fibromyalgia
What this study did
Phase 4 (6)
Diabetic Peripheral Neuropathic Pain
NCT07800468 · Wah Medical college , POF hospital
2026-12-01 – 2027-04-01 · Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies, Type 2 Diabetes
What this study did
Major Depressive Disorder
NCT01148472 · H. Lundbeck A/S
2005-09 – 2006-11 · Major Depressive Disorder
What this study did
Other / comorbidity
NCT03249311 · University of Ottawa
2018-03-02 – 2022-05-01 · None (i.e. Healthy Volunteers)
What this study did
NCT03729284 · Pfizer
2020-03-30 – 2020-06-07 · Healthy
What this study did
NCT03794154 · Pfizer
2020-03-30 – 2020-06-05 · Healthy
What this study did
NCT02535000 · Serviço de Anestesiologia de Joinville
2014-01-01 – 2015-10-30 · Intervertebral Disc Degeneration
What this study did
Early phase / not applicable (5)
Fibromyalgia
NCT07203339 · Hospital de Clinicas de Porto Alegre
2025-09-30 – 2028-12 · Fibromyalgia (FM), tDCS, Duloxetine, BDNF, EEG
What this study did
Other / comorbidity
NCT07645482 · Beni-Suef University
2026-07-12 – 2026-08-02 · Peripheral Neuropathy With Type 2 Diabetes
What this study did
NCT06711978 · Pusan National University Yangsan Hospital
2024-12-01 – 2026-04-15 · CIPN, CIPN - Chemotherapy-Induced Peripheral Neuropathy, CIPN in Adjuvant Breast Cancer Patients, Duloxetine, Mirogabalin
What this study did
NCT06301061 · Federico II University
2024-04-01 – 2026-04-01 · Pain, Chronic, Lumbosacral Radiculopathy, Radicular; Neuropathic
What this study did
NCT05560516 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2022-12-01 – 2025-12-31 · Qutenza, Duloxetine, Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
What this study did
Appears in other studies (10)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Major Depressive Disorder
NCT04476030 · Biogen
2020-11-09 – 2021-12-22 · Depressive Disorder, Major
What this study did
NCT03434041 · Janssen Research & Development, LLC
2018-05-25 – 2021-04-13 · Depressive Disorder, Treatment-Resistant
What this study did
Phase 1 (1)
Major Depressive Disorder
NCT06965569 · Alar Pharmaceuticals Inc.
2025-04-21 – 2025-12-30 · Treatment Resistant Depression
What this study did
Phase 4 (1)
Other / comorbidity
NCT00177671 · University of Pittsburgh
2003-12 – 2009-09 · Depression, Dementia
What this study did
Early phase / not applicable (5)
Major Depressive Disorder
NCT00149110 · Hillerod Hospital, Denmark
2005-09 – 2009-03 · Major Depression
What this study did
Other / comorbidity
NCT07593313 · Nanchong Central Hospital
2024-01-01 – 2029-08-01 · Central Post-Stroke Pain
What this study did
NCT07025590 · Guangdong Provincial People's Hospital
2025-04-22 – 2027-03-31 · Cardiovascular Diseases (CVD), Depression Anxiety Disorder
What this study did
NCT06896994 · Beijing Tiantan Hospital
2025-04-01 – 2026-05-01 · Postherpetic Neuralgia
What this study did
NCT05254652 · The Catholic University of Korea
2022-05 – 2023-05 · Osteoarthritis
What this study did

Competitive landscape

Other Serotonin/norepinephrine transporter drugs

Ammoxetine. Compare all 2 Serotonin/norepinephrine transporter drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Diabetic Peripheral Neuropathic Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Duloxetine (Cymbalta): this drugApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)Partial signal
NCT01179672: Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score (Baseline, 12 weeks): Duloxetine -2.4 units on a scale (Standard Error 0.14) vs Placebo -1.97 units on a scale (Standard Error 0.14)
NCT00408993: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score (Baseline and 12 weeks): Duloxetine -2.69 units on a scale (Standard Error 0.19) vs Placebo -2.31 units on a scale (Standard Error 0.18) missed
Capsaicin (Qutenza)ApprovedSmall moleculeTRPV1 (transient receptor potential vanilloid 1) channelReliable signal
NCT01533428: Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8 (Baseline to between Weeks 2 to 8): Capsaicin 8% -27.44% (Standard Deviation 26.79) vs Placebo -20.85% (Standard Deviation 28.92)
NCT01478607: Norfolk QOL-DN total score change from baseline to end of study: 30 min capsaicin + SOC -27.6% (mean difference vs SOC alone -20.9, 90% CI -31.7 to -10.1); 60 min capsaicin + SOC -32.8% (mean difference vs SOC alone -26.1, 90% CI -36.8 to -15.4); SOC alone -6.7%.
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signalNo reviewed efficacy summary in this indication
TapentadolApprovedSmall moleculeMu-opioid receptor and norepinephrine transporter (NET)Reliable signal
NCT01041859: Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12 (Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)): DB Tapentadol ER 0.28 units on a scale (Standard Deviation 2.04) vs DB Placebo 1.3 units on a scale (Standard Deviation 2.43)
NCT00455520: Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12 (Baseline and 12 weeks): Tapentadol ER -0.1 scores on a scale (Standard Deviation 1.69) vs Placebo 1.3 scores on a scale (Standard Deviation 2.41)
CrisugabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsReliable signal
NCT04647773: Week 13 change from baseline in average daily pain score (pooled stages): crisugabalin 40 mg/d -2.24 and 80 mg/d -2.16 vs placebo -1.23 (both P < .001)
MirogabalinPhase 3Small moleculeα2δ-1 subunit of voltage-gated calcium channelsPartial signal
NCT04094662: Average Daily Pain Score (ADPS) change from baseline to week 14, LS mean difference vs placebo: -0.39 (95% CI: -0.74, -0.04), p = 0.0301
NCT02318706: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain (Baseline to Week 14 (post-dose 1 [15 mg QD] and post-dose 2 [20 mg and 30 mg])): DS-5565 15mg QD — Week 1: -0.39 units on a scale (Standard Deviation 0.67); Week 2: -0.6 units on a scale (Standard Deviation 0.9); Week 3: -0.78 units on a scale (Standard Deviation 1.02); Week 4: -0.87 units on a scale (Standard Deviation 1.13); Week 5: -0.97 units on a scale (Standard Deviation 1.2); Week 6: -1.01 units on a scale (Standard Deviation 1.32); Week 7: -1.06 units on a scale (Standard Deviation 1.4); Week 8: -1.07 units on a scale (Standard Deviation 1.49); Week 9: -1.13 units on a scale (Standard Deviation 1.49); Week 10: -1.19 units on a scale (Standard Deviation 1.56); Week 11: -1.23 units on a scale (Standard Deviation 1.57); Week 12: -1.24 units on a scale (Standard Deviation 1.6); Week 13: -1.27 units on a scale (Standard Deviation 1.63); Week 14: -1.34 units on a scale (Standard Deviation 1.74) | DS-5565 20 mg (10 mg BID) — Week 1: -0.4 units on a scale (Standard Deviation 0.85); Week 2: -0.72 units on a scale (Standard Deviation 1.12); Week 3: -0.84 units on a scale (Standard Deviation 1.22); Week 4: -0.94 units on a scale (Standard Deviation 1.38); Week 5: -1.06 units on a scale (Standard Deviation 1.5); Week 6: -1.13 units on a scale (Standard Deviation 1.52); Week 7: -1.13 units on a scale (Standard Deviation 1.59); Week 8: -1.26 units on a scale (Standard Deviation 1.59); Week 9: -1.27 units on a scale (Standard Deviation 1.56); Week 10: -1.33 units on a scale (Standard Deviation 1.65); Week 11: -1.36 units on a scale (Standard Deviation 1.64); Week 12: -1.36 units on a scale (Standard Deviation 1.67); Week 13: -1.43 units on a scale (Standard Deviation 1.72); Week 14: -1.47 units on a scale (Standard Deviation 1.69) | DS-5565 30 mg (15 mg BID) — Week 1: -0.6 units on a scale (Standard Deviation 1.01); Week 2: -1 units on a scale (Standard Deviation 1.27); Week 3: -1.33 units on a scale (Standard Deviation 1.49); Week 4: -1.43 units on a scale (Standard Deviation 1.63); Week 5: -1.48 units on a scale (Standard Deviation 1.68); Week 6: -1.58 units on a scale (Standard Deviation 1.73); Week 7: -1.57 units on a scale (Standard Deviation 1.72); Week 8: -1.53 units on a scale (Standard Deviation 1.79); Week 9: -1.63 units on a scale (Standard Deviation 1.76); Week 10: -1.67 units on a scale (Standard Deviation 1.83); Week 11: -1.69 units on a scale (Standard Deviation 1.8); Week 12: -1.82 units on a scale (Standard Deviation 1.84); Week 13: -1.85 units on a scale (Standard Deviation 1.93); Week 14: -1.88 units on a scale (Standard Deviation 1.88) vs Placebo — Week 1: -0.26 units on a scale (Standard Deviation 0.79); Week 2: -0.46 units on a scale (Standard Deviation 0.96); Week 3: -0.57 units on a scale (Standard Deviation 1.08); Week 4: -0.7 units on a scale (Standard Deviation 1.12); Week 5: -0.84 units on a scale (Standard Deviation 1.17); Week 6: -0.92 units on a scale (Standard Deviation 1.25); Week 7: -1.03 units on a scale (Standard Deviation 1.31); Week 8: -1.09 units on a scale (Standard Deviation 1.39); Week 9: -1.16 units on a scale (Standard Deviation 1.42); Week 10: -1.18 units on a scale (Standard Deviation 1.44); Week 11: -1.25 units on a scale (Standard Deviation 1.46); Week 12: -1.28 units on a scale (Standard Deviation 1.5); Week 13: -1.32 units on a scale (Standard Deviation 1.55); Week 14: -1.37 units on a scale (Standard Deviation 1.6)
Suzetrigine (Journavx)Phase 3Small moleculeVoltage-gated sodium channel NaV1.8Partial signal
NCT05660538: Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70)
HL-1186Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
JMKX000623Phase 2Small moleculeVoltage-gated sodium channel NaV1.8Partial signalNo reviewed efficacy summary in this indication
LY4065967Phase 2Small moleculeAngiotensin II type 2 receptor (AT2R) (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Nispomeben (NRD135S.E1)Phase 2Small molecule—Partial signal
NCT05480228: Primary (11-point NRS pain, change from baseline to week 12): NRD135S.E1 80 mg/day -1.90 (SD 2.38, n=61) vs placebo -1.94 (SD 2.27, n=61); no statistical analysis posted missed
NCT02345291: Placebo-corrected change in weekly mean daily pain intensity (11-point NRS) from run-in to Week 3 (mITT, N=86): -0.42 points for 10 mg (95% CI -1.50, 0.66; p=0.438); -0.82 points for 40 mg (95% CI -1.58, -0.07; p=0.034); -0.66 points for 150 mg (95% CI -1.35, 0.03; p=0.061). missed
PilavapadinPhase 2Small moleculeAP2-associated kinase 1 (AAK1)Partial signal
NCT06203002: Change from baseline to Week 8 in ADPS: -1.74 (10 mg), -1.70 (20 mg/10 mg titration), -1.38 (20 mg), vs -1.31 (placebo); overall primary endpoint p=0.11 (not significant, as the statistical plan required all arms to separate from placebo) missed
NCT04455633: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale (Baseline (Week 2 of the Run-in period) to Week 6): LX9211 100 mg/10 mg -1.39 score on a scale (95% CI -1.77 to -1.01) | LX9211 200 mg/20 mg -1.27 score on a scale (95% CI -1.66 to -0.88) vs Placebo -0.72 score on a scale (95% CI -1.08 to -0.36)
Pirenzepine (topical)Phase 2Small moleculeMuscarinic M1 receptor (antagonist)Partial signalFeatured results are safety only in this race
VX-993Phase 2Small moleculeVoltage-gated sodium channel NaV1.8not yet gradedNo reviewed efficacy summary in this indication
AJH-2947
Phase 1(overall)
Small molecule—Partial signalNo reviewed efficacy summary in this indication
HRS-2129Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
QR-333DiscontinuedBotanical—not yet gradedNo reviewed efficacy summary in this indication
TanezumabDiscontinuedMonoclonal antibodyNerve growth factor (NGF)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cymbalta (Duloxetine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 2Refractory Chronic CoughRecruiting
Est. primary completion 2026-12 · NCT05110144 · CT.gov ↗
What to watch
Phase 4THARecruiting
Est. primary completion 2026-12-01 · NCT06807866 · CT.gov ↗
What to watch
Early phase / not applicableFibromyalgiaEnrolling by invitation
Est. primary completion 2026-12-30 · NCT07326163 · CT.gov ↗
What to watch
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
Phase 2Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2026-12-31 · NCT04560673 · CT.gov ↗
What to watch
2027 (11)
January 2027 (1)
Early phase / not applicableAmantadine, Duloxetine, Pregabalin, Mastectomy, Pain SyndromeRecruiting
Est. primary completion 2027-01-01 · NCT07421427 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2027-03-01 · NCT07431606 · CT.gov ↗
What to watch
Phase 1Post Endodontic Pain, Mechanical Detection Threshold, Mechanical Pain Threshold, Mechanical Pain SensitivityRecruiting
Est. primary completion 2027-03-30 · NCT07400471 · CT.gov ↗
What to watch
Phase 2CIPN - Chemotherapy-Induced Peripheral Neuropathy, PainRecruiting
Est. primary completion 2027-03-30 · NCT06914557 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4Back Pain, LowRecruiting
Est. primary completion 2027-05 · NCT05851976 · CT.gov ↗
What to watch
Phase 4DepressionRecruiting
Est. primary completion 2027-05 · NCT05976347 · CT.gov ↗
What to watch
June 2027 (2)
Early phase / not applicableDiabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2027-06 · NCT07785544 · CT.gov ↗
What to watch
Phase 3Biliary DiseaseRecruiting
Est. primary completion 2027-06-20 · NCT06860984 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chemotherapy-induced Peripheral Neuropathy, Pain, Solid TumorRecruiting
Est. primary completion 2027-07-01 · NCT04970121 · CT.gov ↗
What to watch
Phase 4Knee OsteoarthritisRecruiting
Est. primary completion 2027-07-01 · NCT06423716 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Functional DisorderRecruiting
Est. primary completion 2027-11-01 · NCT06232473 · CT.gov ↗
What to watch
2028 (5)
March 2028 (1)
Phase 4Knee OsteoarthritisRecruiting
Est. primary completion 2028-03-15 · NCT06245109 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ER+ Breast Cancer, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III …Not yet recruiting
Est. primary completion 2028-04-18 · NCT06407401 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2028-06-01 · NCT06614322 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Depression in Old Age, Fragility FractureRecruiting
Est. primary completion 2028-12 · NCT05851898 · CT.gov ↗
What to watch
Phase 4Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee PainRecruiting
Est. primary completion 2028-12 · NCT07759336 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Early phase / not applicableChronic Low-back PainRecruiting
Est. primary completion 2030-02 · NCT07731750 · CT.gov ↗
What to watch
2031 (1)
September 2031 (1)
Phase 2Knee Osteoarthritis, Pain, DepressionNot yet recruiting
Est. primary completion 2031-09-01 · NCT07649291 · CT.gov ↗
What to watch

See the full readout calendar ↗